Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06016634 · ClinicalTrials.gov registry record · Phase 2
Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
A Phase 2 study of Sickle Cell Disease and Avascular Necrosis, sponsored by University of California, Davis.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06016634: Recruiting Phase 2 study of Sickle Cell Disease and Avascular Necrosis, sponsored by University of California, Davis.
NCT06016634 is a Phase 2 study of Sickle Cell Disease and Avascular Necrosis that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 30 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06016634, a Phase 2 study of Sickle Cell Disease and Avascular Necrosis, is actively recruiting participants, sponsored by University of California, Davis.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis
Primary Outcome
Proportion of eligible patients who get recruited to the study; number of enrolled patients who complete 6-month study
Conditions Studied
Interventions
- DRUG Alendronate Sodium
Study Locations (1)
California
- UC Davis Comprehensive Cancer Center - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-02-09 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
What NCT06016634 shows while recruiting
NCT06016634 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (90% lower).
The record links to 5 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which Alendronate Sodium is the first listed.
NCT06016634 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06016634 about?
NCT06016634 is a clinical study titled "Alendronate for Osteonecrosis in Adults With Sickle Cell Disease". A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis
What is the current status of trial NCT06016634?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-02-09. Estimated completion is 2027-12-31.
What conditions does trial NCT06016634 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Avascular Necrosis, Sickle Cell Anemia, Osteonecrosis, Ischemic Necrosis.
What interventions are being tested in trial NCT06016634?
The interventions under investigation include: Alendronate Sodium (DRUG).
Who is sponsoring clinical trial NCT06016634?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06016634 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06016634's enrollment target sits among peer trials
30 139th of 213 higher than 67 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
RECRUITING · Phase 2
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RECRUITING · Phase 2
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
RECRUITING · Phase 2
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI